Last reviewed · How we verify
ibuprofen, dipyrone, acetaminophen
Ibuprofen, dipyrone, and acetaminophen, marketed by Mantecorp Industria Quimica e Farmaceutica Ltd., are established over-the-counter analgesics with a strong presence in the pain management market. A key strength is the key composition patent expiring in 2028, which provides a period of exclusivity and protection against generic competition. The primary risk is the potential increase in competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | ibuprofen, dipyrone, acetaminophen |
|---|---|
| Sponsor | Mantecorp Industria Quimica e Farmaceutica Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Non-Steroidal Anti-Inflammatory Drugs in Acute Myocarditis (PHASE3)
- Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children (PHASE4)
- Delirium in Elderly Patients With Trauma of the Hip (PHASE4)
- Migraine Abortive Treatment
- Comparing Protocols for Analgesia Following Elective Cesarean Section (PHASE4)
- Ibuprofen, Acetaminophen and Dipyrone to Fever Control in Children (PHASE4)
- Study of the Effect of Dipyrone, Ibuprofen, Paracetamol and Parecoxib on the Platelet Aggregation in Analgetic Dosages (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: